SK bioscience
South Korean vaccine maker and CDMO, betting on a pneumococcal shot to reach profit.
On the record
Checkpoint: GBP410 (PCV21) Phase 3 topline readout versus Prevnar 20 and Capvaxive
The call
SK bioscience's manufacturing and government-backed contracts keep it running, but its shot at real profit hinges on a pneumococcal vaccine that won't prove itself against Pfizer and Merck until 2029.
SK bioscience operates vaccine factories and contract drug manufacturing plants in South Korea and Germany that serve governments and global health organizations. These operations are hard to copy because they have official approvals from regulators like the World Health Organization, long-term supply contracts, and require billions of dollars and years to build. However, the company is losing money every year, and its main new vaccine called GBP410 (for pneumococcal disease) faces direct competition from established shots already sold by Pfizer and Merck, which dominate that market. The company's parent, SK Group, is keeping it afloat with loans and backing. The single biggest thing that could change the picture is how well GBP410 performs in its final human testing sometime in the second half of 2026 or 2027: if it works better than Pfizer's current vaccine, the company could become profitable and valuable; if it does not, SK bioscience will remain dependent on lower-paying contract manufacturing work.
Why
01
AI pressure: None apparent. AI trial-design tools like Gates Foundation's ROTOR help speed up SK bioscience's R&D rather than threaten its vaccine business. Could AI do the core job? Unlikely.
02
Bigger players: Pfizer (Prevnar franchise), Merck (Vaxneuvance/Capvaxive). Pfizer and Merck already sell entrenched pneumococcal vaccines while SK bioscience's rival shot, GBP410, won't launch until 2029. Could a giant copy it? Probably.
03
What protects it. WHO-prequalified manufacturing, multilateral supply deals, and SK Group's balance sheet keep the company funded through losses.
What would change this call
GBP410 Phase 3 topline readout reported H2 2026 or 2027. Shows whether SK bioscience can clinically differentiate from Prevnar 20/Capvaxive or falls behind.
SK bioscience FY2026 earnings release in early 2027 vs consensus revenue growth and operating loss. Shows whether IDT Biologika gains offset parent-level losses or the loss deepens.
Delivery outcomes on 2026 UNICEF and PAHO/Colombia tender orders. Shows whether SK bioscience can execute at scale on multilateral supply contracts.
SK bioscience FY2026 earnings release in early 2027 vs consensus revenue growth and operating loss. Shows whether IDT Biologika gains offset parent-level losses or the loss deepens.
Delivery outcomes on 2026 UNICEF and PAHO/Colombia tender orders. Shows whether SK bioscience can execute at scale on multilateral supply contracts.
Key numbers
- 2025 revenue 651.4B won, up 144% YoY
- Operating loss 123.5B won in 2025, third straight annual loss
- IDT Biologika turned profitable with 9.9B won operating income
Named risks
- Three consecutive annual operating losses (2023-2025) with 2026 loss also forecast at ~129.5B won.
- Flagship GBP410 vaccine does not commercialize until 2029, leaving near-term growth dependent on lower-margin CDMO and tender business.
- GBP410 Phase 3 readout (H2 2026/2027) could show non-inferiority or failure against Pfizer/Merck incumbents.
- Headcount and market cap figures are inconsistent across data providers, complicating scale assessment.
- Governance changes at parent SK Chemicals/SK Discovery under Korea's revised Commercial Act could affect board control.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Pfizer (Prevnar franchise) | contesting | GBP410/PCV21 Phase 3 trials across ~19 countries aim to challenge Prevnar, commercial target 2029 |
| Merck (Vaxneuvance/Capvaxive) | contesting | SK bioscience's next-gen pneumococcal candidate targets same market as Merck's franchise, as of 2026-03-23 |
| Serum Institute of India, Bharat Biotech | contesting | Compete directly in low-margin UNICEF/PAHO tender markets where SK bioscience won 2026 flu and varicella orders |
| Sanofi | gaining on | Deepened as co-development partner on GBP410 and pneumococcal pipeline, tech fees up to 530B won, 2026-07-15 |
Questions people ask
- Is SK bioscience profitable in 2026?
- No. SK bioscience posted a third straight annual operating loss of 123.5 billion won in 2025, and analyst consensus (FnGuide, July 2026) projects another operating loss of about 129.5 billion won for 2026 despite revenue growth to 739.2 billion won.
- What is SK bioscience's biggest competitor?
- In its flagship pneumococcal vaccine push, SK bioscience directly challenges Pfizer's Prevnar franchise and Merck's Vaxneuvance/Capvaxive with its GBP410 (PCV21) candidate, co-developed with Sanofi, targeting commercialization around 2029.
- Could AI replace SK bioscience's vaccine business?
- No. SK bioscience is deploying AI, including the Gates Foundation-funded ROTOR platform launched July 2026, only for clinical-trial decision support. Core moats like WHO prequalification, physical manufacturing, and multilateral supply contracts are untouched by AI.
- Who owns SK bioscience?
- SK bioscience is majority owned by parent SK Chemicals, which held about 68.4% at the March 2021 IPO and roughly 66.4% as of March 2026, per Investing.com data. SK Chemicals is itself controlled by holding company SK Discovery.
- Is SK bioscience a safe company to join in 2026?
- Survival looks durable: SK Group backing, a 300 billion won National Growth Fund loan (May 2026), and diversified tender/CDMO revenue. But three consecutive annual operating losses through 2025 and a flagship product not commercializing until 2029 make near-term financial upside uncertain.
- Did the IDT Biologika acquisition help SK bioscience?
- Yes. IDT Biologika, acquired in late 2024, reported 2025 revenue of 465.7 billion won (up about 17% year-on-year) and turned to an operating profit of 9.9 billion won just one year after acquisition, per SK bioscience's February 2026 results.
Timeline
- 2026-07-15Expanded Sanofi partnership for next-gen pneumococcal vaccines, tech fees up to 530B won
- 2026-07-02Named lead organization for Gates Foundation AI platform ROTOR for vaccine R&D
- 2026-07-01Analyst consensus projects 2026 revenue of 739.2B won, operating loss ~129.5B won
- 2026-06-09Licensed injectable rotavirus vaccine technology from U.S. CDC
- 2026-05-29Secured 300B won low-interest loan from Korea's National Growth Fund
- 2026-03-23Company outlines GBP410 Phase 3 progress and audit oversight changes
- 2026-03-19Secured RIGHT Foundation grant for RSV preventive-antibody program RSM01
- 2026-02-04Reported 2025 revenue of 651.4B won, up 144% YoY, operating loss 123.5B won
- 2024Completed acquisition of German CDMO IDT Biologika
- 2021-03-17IPO on KOSPI raised about 1.5 trillion won, shares surged 30% on debut
Revision history
30 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- SK Bioscience
- Who Owns SK Bioscience Co? (2026-03-12)
- South Korea IPO boom continues as shares in vaccine firm SK Bioscience surge 30% on debut (2021-03-17)
- 302440 Company Profile
- SK bioscience revenue jumps 144% in 2025 as IDT turns profitable (2026-02-04)
- SK bioscience narrows loss in 2025 on vaccine exports and IDT turnaround (2026-02-04)
- SK bioscience bolsters audit oversight and trims pay cap as it targets rebound (2026-03-23)
- SK Bioscience Accelerates Growth on Vaccine and CDMO Momentum (2026-07-01)
- SK Bioscience Secures 300 Billion Won from National Growth Fund (2026-05-29)
- SK Bioscience Accelerates Global Vaccine Push (2026-07-15)
- SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development (2026-06-09)
- SK bioscience Secures Funding to Advance RSV Preventive Antibody Development (2026-03-19)